Amundi reduced its stake in shares of Inari Medical, Inc. (NASDAQ:NARI – Free Report) by 10.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 201,366 shares of the company’s stock after selling 23,076 shares during the period. Amundi owned 0.34% of Inari Medical worth $10,280,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. PNC Financial Services Group Inc. raised its holdings in Inari Medical by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,550 shares of the company’s stock valued at $130,000 after acquiring an additional 128 shares during the last quarter. Arizona State Retirement System raised its holdings in Inari Medical by 0.9% in the 4th quarter. Arizona State Retirement System now owns 15,196 shares of the company’s stock valued at $776,000 after acquiring an additional 129 shares during the last quarter. Ieq Capital LLC raised its holdings in Inari Medical by 0.3% in the 4th quarter. Ieq Capital LLC now owns 50,198 shares of the company’s stock valued at $2,563,000 after acquiring an additional 145 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in Inari Medical by 128.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 634 shares of the company’s stock valued at $33,000 after acquiring an additional 356 shares during the last quarter. Finally, KBC Group NV raised its holdings in Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after acquiring an additional 498 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors and hedge funds.
Inari Medical Stock Performance
Shares of Inari Medical stock opened at $79.97 on Friday. The company has a fifty day moving average price of $78.86 and a 200 day moving average price of $58.54. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $79.99. The stock has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02.
Analyst Ratings Changes
Read Our Latest Stock Report on Inari Medical
Insider Buying and Selling at Inari Medical
In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the transaction, the chief executive officer now directly owns 439,310 shares of the company’s stock, valued at $24,289,449.90. This represents a 0.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William Hoffman sold 60,000 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $55.66, for a total transaction of $3,339,600.00. Following the completion of the transaction, the director now directly owns 441,233 shares of the company’s stock, valued at approximately $24,559,028.78. The trade was a 11.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 263,000 shares of company stock valued at $15,599,470 in the last ninety days. Insiders own 10.60% of the company’s stock.
About Inari Medical
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
Further Reading
- Five stocks we like better than Inari Medical
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Options Trading – Understanding Strike Price
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Want to see what other hedge funds are holding NARI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inari Medical, Inc. (NASDAQ:NARI – Free Report).
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.